Geriatric Psoriasis
Özet
Psoriasis is a chronic inflammatory skin disease triggered by genetic and environmental factors. Although it can occur at any age, its prevalence is increasing in aging populations, making psoriasis an important condition in geriatric care. The higher prevalence of comorbidities such as cardiovascular disease, diabetes, and arthritis in geriatric psoriasis complicates the management of the disease. The disease can present in various forms including plaque, inverse, guttate, pustular and erythrodermic psoriasis, with plaque psoriasis being the most common subtype among the elderly. However, the inverse and guttate types are more common in this population than in younger adults.
The management of geriatric psoriasis requires careful consideration of comorbidities, potential drug interactions, and overall quality of life, which is influenced by the psychological and social effects of the disease. As the elderly population increases, psoriasis in geriatric patients will become a significant problem, requiring greater awareness and specialised care strategies.
Referanslar
Greb J. Psoriasis. Nature reviews. Disease primers 2, 16082. 2016.
Henseler T, Christophers E. Psoriasis of early and late onset: characterisation of two types of psoriasis vulgaris. Journal of the American Academy of Dermatology. 1985;13(3):450-456.
Balato N, Patruno C, Napolitano M, et al. Managing moderate-to-severe psoriasis in the elderly. Drugs & aging. 2014;31:233-238.
Aggarwal D, Arumalla N, Jethwa H, et al. The use of biomarkers as a tool for novel psoriatic disease drug discovery. Expert Opinion on Drug Discovery. 2018;13(9):875-887.
Kalay Yildizhan I, Sürgün E, Kundakcı N. Epidemiological and clinical characteristics, treatments, and comorbidities in elderly patients with psoriasis and the evaluation of patients according to the age of onset. Turk Geriatrics Journal. 2020.
Yosipovitch G, Tang MB. Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options. Drugs Aging. 2002;19(11):847-863.
Balato N, Patruno C, Napolitano M, et al. Managing moderate-to-severe psoriasis in the elderly. Drugs Aging. 2014;31(4):233-238.
Bell LM, Sedlack R, Beard CM, et al. Incidence of psoriasis in Rochester, Minn, 1980- 1983. Archives of dermatology. 1991;127(8):1184-1187.
Yap K, Siew M, Goh C. At The National Skin Centre (Singapore) 1990. Singapore Med J. 1994;35:147-150.
Liao Y, Chen K, Tseng M, et al. Pattern of skin diseases in a geriatric patient group in Taiwan: a 7-year survey from the outpatient clinic of a university medical centre. Dermatology. 2001;203(4):308-313.
Phan C, Sigal ML, Estève E, et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. Journal of the European Academy of Dermatology and Venereology. 2016;30(1):78-82.
Napolitano M, Balato N, Ayala F, et al. Psoriasis in elderly and non-elderly population: clinical and molecular features. G Ital Dermatol Venereol. 2016;151(6):587-595.
Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clinical Medicine. 2021;21(3):170-173.
Kimmel GW, Lebwohl M. Psoriasis: overview and diagnosis. Evidence-Based Psoriasis: Diagnosis and Treatment. 2018:1-16.
Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. 2008;58(5):826-850.
Ayala F. Clinical presentation of psoriasis. Reumatismo. 2007;59(s1):40-45.
Chen C, Che K, Guo Y, et al. Effect of the age of onset on epidemiology, clinical features, and comorbidity of geriatric psoriasis. J Dermatol. 2023;50(9):1156-1161.
Zelickson BD, Muller SA. Generalised pustular psoriasis: a review of 63 cases. Archives of dermatology. 1991;127(9):1339-1345.
Tay YK, Tham SN. The profile and outcome of pustular psoriasis in Singapore: a report of 28 cases. International journal of dermatology. 1997;36(4):266-271.
Oh EH, Ro YS, Kim JE. Epidemiology and cardiovascular comorbidities in patients with psoriasis: A Korean nationwide population-based cohort study. The Journal of dermatology. 2017;44(6):621-629.
Lisi P. Differential diagnosis of psoriasis. Reumatismo. 2007;59(s1):56-60.
Murphy M, Kerr P, Grant-Kels JM. The histopathological spectrum of psoriasis. Clinics in dermatology. 2007;25(6):524-528.
Aydin O, Engin B, Oguz O, et al. Non-pustular palmoplantar psoriasis: is histological differentiation from eczematous dermatitis possible? Journal of cutaneous pathology. 2008;35(2):169-173.
Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. Journal of the American Academy of Dermatology. 2017;76(3):377-390.
Egeberg A, Skov L, Joshi AA, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. Journal of the American Academy of Dermatology. 2017;77(4):650-656. e653.
Morici N, Ferri L, Alicandro G, et al. Psoriasis and the risk of acute coronary syndrome in the elderly. International Journal of Cardiology. 2018;273:44-46.
Fleischer Jr A, Feldman S, Rapp S, et al. Alternative therapies commonly used within a population of patients with psoriasis. Cutis. 1996;58(3):216-220.
Ginsburg IH, Link BG. Psychosocial consequences of rejection and stigma feelings in psoriasis patients. International journal of dermatology. 1993;32(8):587-591.
Fortune D, Main C, O'sullivan T, et al. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. British Journal of Dermatology. 1997;137(5):755-760.
Ramsay B, O'REAGAN M. A survey of the social and psychological effects of psoriasis. British Journal of Dermatology. 1988;118(2):195-201.
Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology. 1999;41(3):401- 407.
McKenna K, Stern R. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. Journal of the American Academy of Dermatology. 1997;36(3):388-394.
Finlay AY, Coles E. The effect of severe psoriasis on the quality of life of 369 patients. British Journal of Dermatology. 1995;132(2):236-244.
Goldsmith LA, Fisher M, Wacks J. Psychological characteristics of psoriatics: implications for management. Archives of Dermatology. 1969;100(6):674-676.
Hardy G, Cotterill J. A study of depression and obsessionality in dysmorphophobic and psoriatic patients. The British Journal of Psychiatry. 1982;140(1):19-22.
Feldman SR, Fleischer Jr AB, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. Journal of the American Academy of Dermatology. 1997;37(4):564-569.
Nevitt G, Hutchinson P. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. British Journal of Dermatology. 1996;135(4):533- 537.
Rapp SR, Cottrell C, Leary M. Social coping strategies associated with quality of life decrements among psoriasis patients. British Journal of dermatology. 2001;145(4):610-616.
